AVIR insider buying and SEC filings, explained
Atea Pharmaceuticals, Inc. · CIK 1593899
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$51K
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 18, 2025–May 18, 2026 | Purchase (code P) Amended filing | Polly A. Murphy (Director) bought 12,200 shares between May 18, 2025 and May 18 at about $4.17 ($51K), reported as a purchase (code P). Holdings up 15% to 92,145 shares. Not marked as a 10b5-1 plan trade. This amends a filing from May 20. | SEC filing Filed May 21, 2026 |
15 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow AVIR in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.